CLAIMS

1. A recombinant binding protein comprising an ankyrin repeat domain with binding specificity for CD3, wherein said ankyrin repeat domain comprises an ankyrin repeat module having an amino acid sequence selected from the group consisting of (1) SEQ ID NOs: 5 to 9 and (2) sequences in which up to 9 amino acids in any of SEQ ID NOs: 5 to 9 are substituted by other amino acids.

2. The binding protein of claim 1, wherein said ankyrin repeat module is a first ankyrin repeat module and wherein said ankyrin repeat domain further comprises a second ankyrin repeat module having an amino acid sequence selected from the group consisting of (1) SEQ ID NOs: 5 to 9 and (2) sequences in which up to 9 amino acids in any of SEQ ID NOs: 5 to 9 are substituted by other amino acids.

3. The binding protein of claim 2, wherein said first ankyrin repeat module comprises an amino acid sequence selected from the group consisting of (1) SEQ ID NO: 5 and (2) sequences in which up to 9 amino acids in SEQ ID NO: 5 are substituted by other amino acids, and wherein said second ankyrin repeat module comprises an amino acid sequence selected from the group consisting of (1) SEQ ID NO: 6 and (2) sequences in which up to 9 amino acids of SEQ ID NO: 6 are substituted by other amino acids.

4. The binding protein of claim 2, wherein said first ankyrin repeat module comprises an amino acid sequence selected from the group consisting of (1) SEQ ID NO: 7 and (2) sequences in which up to 9 amino acids in SEQ ID NO: 7 are substituted by other amino acids, and wherein said second ankyrin repeat module comprises an amino acid sequence selected from the group consisting of (1) SEQ ID NO: 6 and (2) sequences in which up to 9 amino acids of SEQ ID NO: 6 are substituted by other amino acids.

5. The binding protein of claim 2, wherein said first ankyrin repeat module comprises an amino acid sequence selected from the group consisting of (1) SEQ ID NO: 7 and (2) sequences in which up to 9 amino acids in SEQ ID NO: 7 are substituted by other amino acids, and wherein said second ankyrin repeat module comprises an amino acid sequence selected from the group consisting of (1) SEQ ID NO: 8 and (2) sequences in which up to 9 amino acids of SEQ ID NO: 8 are substituted by other amino acids.

6. The binding protein of claim 2, wherein said first ankyrin repeat module comprises an amino acid sequence selected from the group consisting of (1) SEQ ID NO: 7 and (2) sequences in which up to 9 amino acids in SEQ ID NO: 7 are substituted by other amino acids, and wherein said second ankyrin repeat module comprises an amino acid sequence selected from the group consisting of

(1) SEQ ID NO: 9 and (2) sequences in which up to 9 amino acids of SEQ ID NO: 9 are substituted by other amino acids.

7. The binding protein of any of claims 2 to 6, wherein said first ankyrin repeat module is located N-terminally of said second ankyrin repeat module within said ankyrin repeat domain.

8. A recombinant binding protein comprising an ankyrin repeat domain with binding specificity for CD3, wherein said ankyrin repeat domain comprises an amino acid sequence with at least 80% amino acid sequence identity with any one of SEQ ID NOs: 1 to 4, and wherein A at the second last position of SEQ ID NOs: 1 to 4 is optionally substituted by L, and/or A at the last position of SEQ ID NOs: 1 to 4 is optionally substituted by N.

9. The binding protein of any of the preceding claims, wherein said binding protein binds human CD3 in PBS with a dissociation constant (K_D) below 10^{-7}M.

10. The binding protein of any of the preceding claims, wherein said binding protein binds human CD3 on T cells with an EC_{50} ranging from 2 to 900 nM.

11. The binding protein of any of the preceding claims, wherein said binding protein further comprises a binding agent with binding specificity for a disease-associated antigen.

12. The binding protein of any of the preceding claims, wherein said binding protein further comprises a half-life extending moiety.

13. A nucleic acid encoding the binding protein of any of the preceding claims.

14. A pharmaceutical composition comprising the binding protein of any of claims 1 to 12 or the nucleic acid of claim 13, and optionally a pharmaceutically acceptable carrier and/or diluent.

15. ~~A method of treating a medical condition, the method comprising the step of administering to a patient in need thereof a therapeutically effective amount~~Use of the binding protein of any one of claims 1 to 12, the nucleic acid of claim 13 or the pharmaceutical composition of claim 14, in the manufacture of a medicament for treating a medical condition.

16. The binding protein of any one of claims 1 to 12, the nucleic acid of claim 13 or the pharmaceutical composition of claim 14, for use in therapy.